Novel therapies in myeloid neoplasms show limited benefit and increased costs over 15 years of follow-up in Southern Finland.

Theerin Lanamtieng, Anna Mervaala-Muroke, Laura Toivanen, Kimmo Porkka, Oscar Brück

Abstract readObservational Study

In one paragraph

Observational study in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Theerin LanamtiengHematoscope Lab, Comprehensive Cancer Center, Department of Oncology, Department of Clinical Chemistry, HUS Diagnostic Center, Helsinki University Hospital, University of Helsinki, Helsinki University Hospital, University of Helsinki, Tukholmankatu 8C, Helsinki, P.O. Box 705, FIN-00290, Finland. theerin.lanamtieng@helsinki.fi.ORCID http://orcid.org/0000-0001-6690-3024

Anna Mervaala-MurokeHematoscope Lab, Comprehensive Cancer Center, Department of Oncology, Department of Clinical Chemistry, HUS Diagnostic Center, Helsinki University Hospital, University of Helsinki, Helsinki University Hospital, University of Helsinki, Tukholmankatu 8C, Helsinki, P.O. Box 705, FIN-00290, Finland.

Laura ToivanenHematoscope Lab, Comprehensive Cancer Center, Department of Oncology, Department of Clinical Chemistry, HUS Diagnostic Center, Helsinki University Hospital, University of Helsinki, Helsinki University Hospital, University of Helsinki, Tukholmankatu 8C, Helsinki, P.O. Box 705, FIN-00290, Finland.

Kimmo PorkkaHematoscope Lab, Comprehensive Cancer Center, Department of Oncology, Department of Clinical Chemistry, HUS Diagnostic Center, Helsinki University Hospital, University of Helsinki, Helsinki University Hospital, University of Helsinki, Tukholmankatu 8C, Helsinki, P.O. Box 705, FIN-00290, Finland.

Oscar BrückHematoscope Lab, Comprehensive Cancer Center, Department of Oncology, Department of Clinical Chemistry, HUS Diagnostic Center, Helsinki University Hospital, University of Helsinki, Helsinki University Hospital, University of Helsinki, Tukholmankatu 8C, Helsinki, P.O. Box 705, FIN-00290, Finland. oscar.bruck@hus.fi.ORCID http://orcid.org/0000-0002-7842-9419

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past two decades, targeted therapies have been adopted in the treatment of myeloid neoplasms. However, their impact on overall survival (OS) and healthcare spending remains uncertain. We performed a comprehensive retrospective observational study on patients with acute myeloid leukemia (AML, n = 684), myelodysplastic syndrome (MDS, n = 899) and myelofibrosis (MF, n = 276) diagnosed between 2009 and 2023 in a large hospital district in Southern Finland. During this 15-year period, the median age increased across all cohorts. OS remained unchanged after adjusting for age, comorbidity index and risk score in AML (HR 0.77, 95% CI 0.59–1.02), MDS (HR 1.03, 95% CI 0.81–1.31), and MF (HR 0.70, 95% CI 0.45–1.08). However, progression-free survival (PFS) improved among AML patients. For subgroup analyses, OS and PFS improved in AML receiving high-dose chemotherapy, mostly due to better stratification to fit and unfit treatment regimens. In MDS and MF cohorts, no OS benefit was observed in any subgroup. Hospitalization and drug expenses were the primary components in all cohorts and increased notably in AML and MF patients due to novel treatments. Advances in clinical care and adoption of novel agents show limited benefit but have gradually increased their financial burden. Future research should prioritize less toxic, outpatient-based treatments to enhance outcome and cost-effectiveness.

Indexed as

Health Care CostsLeukemia, Myeloid, AcuteMyelodysplastic SyndromesPrimary MyelofibrosisAdultAgedAged, 80 and overCost-Benefit AnalysisFemaleFinlandFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesAcute myeloid leukemiaCost analysisHealth economicsMyelodysplastic syndromesMyelofibrosisSurvivals

Identifiers

PMID41649561

DOI10.1007/s00277-026-06863-y

PMCPMC12881082

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.